Bio Elpida, your CDMO for Stem Cell Therapy and Regenerative Medicine
From Research to Optimisation and GMP Manufacturing
The strong experience of Bio Elpida in cell culture enables the company:
- To develop and adapt R&D manufacturing processes to pharmaceutical constraints
- To perform subcontracting manufacturing of regenerative medicine products based on stem cells
The company is currently involved in 2 such projects for third party companies.
An innovative approach using the pluripotency of primary cells
The goal of regenerative medicine is to repair damaged human tissues. This therapeutic approach relies on the capacities of primary cells to divide and differentiate into some cell type (pluripotency).
Practically, primary cells are isolated, purified and cultured in vitro while maintaining their pluripotency. There are then injected to a patient in order to directly regenerate the wounded organ. In some cases, an intermediate step is required: an in vitro pre-differentiation step.
Regenerative medicine could be used to cure several diseases: some cancers, diabetes, neurodegenerative diseases, side effects of radiotherapy…